Researchers have successfully demonstrated a groundbreaking approach to Parkinson’s disease treatment through BBM-P002, a dual-target gene therapy that addresses two critical bottlenecks in dopamine production. Published in Nature Medicine, this phase 1 clinical trial enrolled 12 patients with moderate-to-severe Parkinson’s disease and delivered genes encoding both tyrosine hydroxylase and L-DOPA decarboxylase directly to the striatum via stereotactic surgery.
Unlike conventional single-pathway therapies, BBM-P002’s simultaneous targeting of two enzymes represents a more comprehensive approach to restoring dopamine synthesis capacity in affected brain regions. The trial demonstrated an excellent safety profile with no serious adverse events attributed to the gene therapy, while participants maintained sustained motor function improvements for 12 months following a single injection.
These results suggest that multi-target gene therapy strategies may offer superior efficacy for neurodegenerative disorders where multiple enzymatic steps are impaired. Read the full article on GMJ Newsroom.
Was this article helpful?
